Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting ... ( TUSTIN Calif. Nov. 25 /- PeregrinePha...)

HOME >> MEDICINE >> NEWS

Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies

Date:11/25/2008

TUSTIN, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of serious viral infections and cancer, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids. The aminophospholipid family of phospholipids, including phosphatidylserine (PS), represents a novel target for anti-viral therapies. The new patent follows publication this week of a study in Nature Medicine that supports the broad anti-viral potential of the company's anti-phospholipid platform, showing that phospholipid-targeting drugs can cure lethal virus infections in animal disease models.

"Issuance of this broad anti-viral patent significantly expands our intellectual property leadership the field of phospholipid-targeting antibodies," said Steven W. King, president and CEO of Peregrine. "Antibodies falling under the scope of this new patent are already showing promise in preclinical studies of lethal virus diseases including hemorrhagic fever and AIDS."

The new patent's allowed claims include methods of treating a broad spectrum of viral infections, including human immunodeficiency virus (HIV), influenza, hepatitis C virus (HCV) and cytomegalovirus (CMV), using one or more anti-phospholipid antibodies that directly bind to an aminophospholipid target, either alone or in combination with other anti-viral agents. The patent also covers anti-viral immunoconjugate compositions, methods and other combinations of anti-phospholipid antibodies and anti-viral agents.

"We believe this is a significant patent in the anti-viral field and we are especially please
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
2. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
3. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
4. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
5. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
6. Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at the 20th Annual Piper Jaffray Health Care Conference
8. King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion
9. Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the Presidents Council on Physical Fitness and Sports, to Board of Directors
10. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
11. Keryx Biopharmaceuticals Receives Nasdaq Notification

Post Your Comments:

Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting ...( TUSTIN Calif. Nov. 25 /- PeregrinePha...),Health